Medicenna Extends Period to Exercise Certain Warrants
05 Julho 2023 - 8:00AM
Medicenna Therapeutics Corp. (“Medicenna” or the “Company”)
(NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company,
today announced that it has received conditional approval from the
Toronto Stock Exchange to extend the expiry date of a total of
1,549,052 outstanding common share purchase warrants of the Company
(the “Warrants”) originally issued on October 17, 2019 as
part of a public offering of units of the Company. Each warrant is
exercisable for a common share of the Company (the “Common
Shares”) at a price of $1.75 per Common Share and set to expire on
July 17, 2023.
The Company has extended the expiry date of such
Warrants until October 17, 2024, with such extension being
effective on July 17, 2023. All other terms of the Warrants,
including the exercise price, remain unchanged. None of the
outstanding warrants are held by insiders.
About Medicenna
Medicenna is a clinical stage immunotherapy
company focused on the development of novel, highly selective
versions of IL-2, IL-4 and IL-13 Superkines and first in class
Empowered Superkines. Medicenna’s long-acting IL-2 Superkine,
MDNA11, is a next-generation IL-2 with superior CD122 (IL-2
receptor beta) binding without CD25 (IL-2 receptor alpha) affinity
thereby preferentially stimulating cancer killing effector T cells
and NK cells. Medicenna’s early-stage BiSKITs™ program,
(“Bifunctional SuperKine ImmunoTherapies”) is designed to enhance
the ability of Superkines to treat immunologically “cold” tumors.
Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55),
has been studied in 5 clinical trials including a Phase 2b trial
for recurrent GBM, the most common and uniformly fatal form of
brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug
status from the FDA and FDA/EMA, respectively.
Forward-Looking Statements
This news release contains forward-looking
statements under applicable securities laws and relate to the
future operations of the Company and other statements that are not
historical facts including, but not limited to, statements related
to the extension of the term of the Warrants. Forward-looking
statements are often identified by terms such as “will”, “may”,
“should”, “anticipate”, “expects”, “believes”, “seeks” and similar
expressions. All statements other than statements of historical
fact, included in this release, are forward-looking statements that
are subject to risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and actual results
and future events could differ materially from those anticipated in
such statements. Important factors that could cause actual results
to differ materially from the Company’s expectations include the
risks detailed in the annual information form and Form 20-F of the
Company and in other filings made by the Company with the
applicable securities regulators from time to time
in Canada and the United States.
The reader is cautioned that assumptions used in
the preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to
differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management, may prove to be incorrect and actual results may differ
materially from those anticipated. Forward-looking statements
contained in this news release are expressly qualified by this
cautionary statement. The forward-looking statements contained in
this news release are made as of the date hereof and except as
required by law, we do not intend and do not assume any obligation
to update or revise publicly any of the included forward-looking
statements.
Further Information
For further information about the Company please contact:
Elizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com
Media Contact
For media inquiries, please contact:
Tony Russo, Russo Partners, 212-845-4251, tony.russo@russopartnersllc.com
Medicenna Therapeutics (NASDAQ:MDNA)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Medicenna Therapeutics (NASDAQ:MDNA)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024